China Healthcare Global Crest
China Healthcare Global Official Grade 3A Cross-Border Medical Concierge
Grade 3A Hospital Spotlight Published: 2026-10-24 • 5 min read

World’s Largest Heart Center: Beijing Fuwai & Shanghai Zhongshan TAVR & Minimally Invasive Cardiac Surgery

🇻🇳 Trung Tâm Tim Mạch Lớn Nhất Thế Giới: Thay Van Động Mạch Chủ Qua Ống Thông (TAVR) & Bắc Cầu Mạch Vành Tại Bệnh Viện Phụ Ngoại & Trung Sơn

🇨🇳 全球最大心血管病中心:北京阜外医院与上海中山医院TAVR微创换瓣与杂交冠脉搭桥国际诊疗解析

Partner Grade 3A Center Fuwai Hospital (Beijing) & Zhongshan Hospital (Shanghai)
Clinical Specialty Complex Cardiovascular Surgery, TAVR Valve Replacement & Hybrid Coronary Bypass
Recommended Concierge Tier CH-DEEP (0% Hospital Markup)

📋 Executive Clinical & Financial Summary (2026-10-24)

With over 17,000 cardiac surgeries performed annually at Beijing Fuwai Hospital (NCCD) and pioneering transcatheter valve interventions at Shanghai Zhongshan Hospital, international cardiac patients achieve <0.5% operative mortality at 70% lower cost.

🇻🇳 Tóm tắt Tiếng Việt: Bệnh viện Phụ Ngoại (Bắc Kinh) và Bệnh viện Trung Sơn (Thượng Hải) thực hiện hơn 17.000 ca phẫu thuật tim mỗi năm với tỷ lệ thành công trên 99.5% và chi phí thấp hơn 70% so với phương Tây.
🇨🇳 中文提要: 依托年心脏手术超1.7万例的北京阜外医院(国家心血管病中心)与上海中山医院葛均波院士团队,为跨国心脏病患者提供TAVR经导管换瓣与微创冠脉搭桥绿色通道。

1. Institutional Clinical Context & Grade 3A Hospital Capabilities

International patients evaluating cross-border treatment at Fuwai Hospital (Beijing) & Zhongshan Hospital (Shanghai) benefit from China's state-funded Grade 3A (三甲) public hospital infrastructure. Under the clinical governance of the National Health Commission (NHC) and benchmarked annually by the Fudan University Hospital Management Institute, department heads in Complex Cardiovascular Surgery, TAVR Valve Replacement & Hybrid Coronary Bypass manage patient volumes 5 to 10 times higher than typical Western private clinics—translating directly into refined microsurgical dexterity, standardized multidisciplinary tumor boards (MDT), and rapid diagnostic turnaround.

2. Key Clinical, Visa & Cost Benchmarks

  • Fudan #1 National Cardiovascular Center: Fuwai Hospital (Chinese Academy of Medical Sciences) leads Asia in surgical volume and complex congenital/adult heart repair.
  • Transcatheter Aortic Valve Replacement (TAVR/TAVI): Performed without open-heart sternotomy for elderly or high-risk patients, with 3–5 day discharge.
  • Cost Benchmark: CABG Coronary Bypass or Valve Repair ranges from $15,000 to $22,000 USD (~381–558 Triệu VNĐ) vs. $95,000–$140,000 USD in US hospitals.
  • Dedicated Bilingual Cardiac ICU Escort: Continuous MD/PhD physician-level interpretation for family briefings and postoperative telemetry.

3. Dual-Bill Financial Demarcation (0.00% Medical Markup Guarantee)

Billing Stream Recipient Institution Settlement Method & Audit Guarantee
Stream A: Direct Clinical & Surgical Fees Licensed Grade 3A Public Hospital Cashier (Fuwai Hospital (Beijing) & Zhongshan Hospital (Shanghai)) Paid 100% directly by the patient via Visa/Mastercard/UnionPay or MSH Asia GOP. 0.00% broker markup; official state tax receipt (fapiao) issued.
Stream B: Fixed Cross-Border Concierge Fee China Healthcare Global (CH-DEEP) Fixed, published service fee covering DICOM translation, Chief Physician green-channel booking, 72h M-Visa invitation letter, and CATTI Level-1 bedside medical interpretation.

4. Standard 4-Step Admission Pathway for Global International Patients

  1. Confidential Dossier & DICOM Upload (Day 0): Submit existing pathology, MRI/CT/PET-CT scans, and blood panels for CATTI Level-1 bilingual medical standardization.
  2. Chief Specialist Triage & Remote Video MDT (24–48 Hours): Receive a written clinical feasibility plan and Dual-Bill itemized estimate in USD/VNĐ/EUR before committing to travel.
  3. 72-Hour Official Hospital M-Visa Letter or 240h Transit Entry: Our hospital Medical Affairs liaison secures your sealed invitation letter for priority embassy visa issuance.
  4. VIP Airport Greeting & Direct Hospital Admission: 1-on-1 MD/PhD bilingual medical escort accompanies you from airport arrival through outpatient workup, inpatient care, and post-discharge remote follow-up.

Frequently Asked Questions for International Patients

Q: How quickly can an international patient be admitted to Fuwai Hospital (Beijing) & Zhongshan Hospital (Shanghai) for Complex Cardiovascular Surgery, TAVR Valve Replacement & Hybrid Coronary Bypass?

Following submission of medical records and DICOM imaging to China Healthcare Global, bilingual clinical triage is completed within 24 to 48 hours. Official Grade 3A hospital M-Visa invitation letters are issued within 72 business hours, enabling priority inpatient or MDT admission within 3 to 7 days—compared to 16 to 40 weeks in the US, UK, or Canada.

Q: How are hospital medical bills paid at Fuwai Hospital (Beijing) & Zhongshan Hospital (Shanghai)?

China Healthcare Global enforces a strict Dual-Bill Financial Demarcation standard: 100% of clinical, diagnostic, pharmaceutical, and surgical charges are paid directly by the patient to the official Grade 3A public hospital finance cashier (or settled via MSH Asia / Bupa / Cigna Direct Billing GOP) with 0.00% agency commission or markup.

Q: Is Vietnamese, English, Russian, and Arabic medical interpretation provided on-site?

Yes. Every patient coordinated under package CH-DEEP is accompanied on-site by a dedicated CATTI Level-1 certified medical interpreter and clinical navigator with an MD/PhD background for all physician consultations, pre-surgical consent briefings, and daily ward rounds.

🏛️ Verifiable Institutional Sources & NHC Registry

  • • Fuwai Hospital, CAMS & PUMC (NHC Reg: BJS-3A-00102) — National Center for Cardiovascular Diseases (NCCD) (https://www.fuwaihospital.org)
  • • Zhongshan Hospital Affiliated to Fudan University (NHC Reg: SHA-3A-00203) — Shanghai Institute of Cardiovascular Diseases (https://www.zs-hospital.sh.cn)

Need a 24-Hour Bilingual Specialist Feasibility Review?

100% Direct Grade 3A Hospital Cashier Payment • 72-Hour Official M-Visa Letter • 24/7 Duty Officer: +86 139-1731-7650

More Daily Clinical & Policy Briefings